Boswellia is an aromatic resin obtained from the Indian tree, Boswellia serrata, which has been used in traditional Ayurvedic medicine to control pain and inflammation. The main biologically active ingredient of boswellia is boswellic acid.
Current research showed that boswellic acid expresses strong anti-inflammatory activity and inhibits leukocyte migration, suppresses antibody production and inhibits activation of classical and alternative complement pathways. In addition, boswellic acid expresses analgesic activity, prevents degradation of cartilage matrix and reduces bronchospasm.
Curcumin [1, 7-bis (4-hydroxy-3-methoxyphenyl)-1, 6 heptadiene-3, 5-dione] is an orange-yellow component of turmeric (Curcuma longa), a spice often found in curry powder.
Curcumin possesses a variety of biologic and pharmacologic activities, including anti-inflammatory, anti-oxidant, and anticarcinogenic ones. It induces detoxifying enzymes such as glutathione S-transferase and as such may find application as a cancer prevention agent.
Curcumin is a potent inhibitor of COX-2, lipooxygenase, ornithine decarboxylase (ODC), nuclear factor-kB, c-Jun N-terminal kinase and protein kinase C and has also been demonstrated to play a vital role against pathological conditions such as atherosclerosis and neurodegenerative diseases.
Potential side effects:
- Stomach discomfort
- Acid reflux (heartburn)
- Burning upon urination
Potential drug interactions:
- Montelukast (Singulair)
- Fluconazole (Diflucan)
- Chronic anticoagulation therapy
Contents: 60 VCaps
The recommended dose of Boswellia/Curcumin blend is 1 capsule 3 times a day with meals containing plant or animal fat. Those exceeding the recommended doses must do so under the supervision of their physician due to the increased risk of potential side effects.
Contains no: sugar, salt, starch, yeast, wheat, corn, milk, preservatives.
Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet. 2011 Jun 1;50(6):349-69.
Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Med. 2006 Oct;72(12):1100-16.
Bright JJ. Curcumin and autoimmune disease. Adv Exp Med Biol. 2007;595:425-51.
Henrotin Y, Clutterbuck AL, Allaway D, Lodwig EM, Harris P, Mathy-Hartert M, Shakibaei M, Mobasheri A. Biological actions of curcumin on articular chondrocytes. Osteoarthritis Cartilage. 2010 Feb;18(2):141-9.
Poeckel D, Werz O. Boswellic acids: biological actions and molecular targets. Curr Med Chem. 2006;13(28):3359-69.
Rajasekaran SA. Therapeutic potential of curcumin in gastrointestinal diseases. World J Gastrointest Pathophysiol. 2011 Feb 15;2(1):1-14.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
All information contained on this website is intended for informational and educational purposes only, and is not intended nor suited to be a replacement or substitute for professional medical treatment or for professional medical advice relative to a specific medical question or condition.
- 360 EPA/240 DHA (fish oil)
- Black Currant Seed Oil
- Cat's Claw Maximum Strength
- Devil's Claw Plus
- Cancer Prevention
- Inflammatory Bowel Disease/Ulcerative Colitis
- Parkinson's Disease
- Rheumatoid Arthritis